Who makes Very Low Dose Quillivant XR?

Very Low Dose Quillivant XR is developed by Seattle Children's Hospital.

What development phase is Very Low Dose Quillivant XR in?

Very Low Dose Quillivant XR is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Very Low Dose Quillivant XR

Seattle Children's Hospital · FDA-approved active Small molecule Quality 0/100

Very Low Dose Quillivant XR, marketed by Seattle Children's Hospital, is a unique extended-release formulation targeting a specific patient segment. The key composition patent expires in 2028, providing a strong barrier to generic competition until then. The primary risk lies in the lack of clear revenue data and key trial results, which may affect investor confidence and market adoption.

At a glance

Generic name	Very Low Dose Quillivant XR
Also known as	Methylphenidate HCl
Sponsor	Seattle Children's Hospital
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Very Low Dose Quillivant XR CI brief — competitive landscape report
Very Low Dose Quillivant XR updates RSS · CI watch RSS
Seattle Children's Hospital portfolio CI